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Purpose: The third variable (V3) loop of the human immunodeficiency virus type 
1 (HIV-1) envelope glycoprotein has been intensively studied for AIDS vaccine 
development. Bacille Calmette-Guérin (BCG) is widely used to immunize against 
tuberculosis and has many advantages as a vaccine vehicle, such as low toxicity, ad-
juvant potential, low cost, and long-lasting immune-inducing capacity. This work 
was initiated to investigate the immunogenicity of recombinant BCG (rBCG-
mV3) designed to express trimeric HIV-1 V3 loop (mV3) in rBCG-mV3-immu-
nized animals. Materials and Methods: HIV-1 V3-concatamer was cloned into 
pMV261, a BCG-expression vector, and then rBCG-mV3 was constructed by in-
troducing the recombinant plasmid (pMV-V3). The recombinant BCG was exam-
ined with regard to its expression of V3-concatamer and the genetic stability in 
vivo and in vitro. The immune responses induced by recombinant BCG were test-
ed in immunized mice and guinea pigs. Results: The rBCG-mV3 expressed de-
tectable amounts of V3-concatamer when induced by single heat-shock. The re-
combinant BCG was genetically stable and maintained the introduced mV3 gene 
for several weeks. V3-specific antibodies were clearly detected 6 weeks after inoc-
ulation. The antibody titer rapidly increased after immunization up to 10 weeks, 
and then maintained for over 4 weeks. IgG2a was prevalent in the V3-specific an-
tiserum. The recombinant BCG was also effective in inducing delayed-type hyper-
sensitivity responses in the immunized guinea pigs. rBCG-immunized mice re-
tained substantial amounts of V3-specific T cells in the spleen, even 5 months after 
the first immunization. Conclusion: Recombinant BCG-mV3 is very efficient in 
inducing humoral and long-lasting cell-mediated immunity against HIV-1 V3 in 
the immunized animals. 
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INTRODUCTION
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structed recombinant BCG vaccines expressing foreign an-
tigens with sufficient immunogenicity to induce humoral 
and cellular immunity that could protect the host from viral, 
bacterial, or parasitic infections.17,18 Whereas, current devel-
opment of HIV-1 vaccine is strongly recommended to in-
duce humoral and cellular immunity against HIV-1 after 
vaccination.19-21 In this aspect, recombinant BCG can be a 
fascinating vaccine vector for the development of HIV-1 
vaccine.19-21 
In the present study, recombinant BCG (rBCG-mV3) 
was constructed which expressed the trimeric HIV-1 V3 
loop (mV3), and the immunogenicity of rBCG-mV3 has 
been determined in experimental animals.  
MATERIALS AND METHODS
All of the experiments were performed based on the pro-
cess shown in Fig. 1. 
Plasmid construction and expression  
V3 was amplified by polymerase chain reaction (PCR) from 
cDNA of HXB2 with PCR primers covering the V3 region. 
Sense 5’ ACC CGG GAT CCA TGT ACA AGA CCC AAC 
AAC-3’ (BamHI), antisense 5’ CTA CA CAA TTC AAG 
GTT ACA ATG TGC TT-3’ (EcoRI), sense 5’ CTA CA GAA 
gp120 has been termed the principal neutralizing determi-
nant of the virus1 and is involved in HIV-1 viral entry.2,3 For 
efficient entry into target cells, HIV-1 requires specific che-
mokine receptors (CCR5, CXCR4) as well as the primary 
receptor, CD4.4,5 The specific amino acids located in the V3 
loop of HIV-1 gp120 play an important role in determining 
cellular tropism and viral preference for the specific chemo-
kine co-receptor for viral entry.6 HIV-1 strains that enter T 
cell lines prefer CXCR4 as a co-receptor, resulting in the 
syncytium-inducing phenotype.7 CCR5 and, less commonly, 
CCR3 or CCR2b, are preferred by HIV-1 strains that enter 
macrophages, resulting in the macrophage-tropic pheno-
type.8 However, V3-specific antibody is rarely detected in 
the serum of patients with AIDS for V3 itself is not highly 
immunogenic.9 Therefore, the V3 loop can be a useful target 
for vaccine development against HIV-1. Several approaches 
have been attempted to intensify the immunogenicity of V3, 
such as substitution of amino acids,10,11 fusion with HBV 
surface Ag12 or toxoid,13 and construction of multimers.14 
Bacille Calmette-Guérin (BCG) is a live, attenuated bo-
vine tubercle bacillus widely used to immunize against tu-
berculosis. BCG has many advantages as a vaccine vehicle, 
such as low toxicity, adjuvant potential, low cost, and long-
lasting immune-inducing capacity. Since Stover, et al.15,16 
developed a shuttle vector (pMV261) that could replicate in 
BCG and Escherichia coli, many researchers have con-
Fig. 1. Schematic illustration of experimental procedure. Phsp60, promoter for heat shock protein; MCS, multiple cloning site; aph, gene 
conferring kanamycin resistance as a selective marker; oriE, E. coli origin of replication; oriM, mycobacterial origin of replication; HIV, human 
immunodefi-ciency virus; V3, third variable.
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umn (Quiagen, Chatsworth, CA, USA) at a flow rate of 10-
15 mL/hour. The column was sequentially washed with 10 
column-volumes of buffer A, 5 column-volumes of buffer 
B [8 M urea, 0.1 M Na-phosphate, and 0.01 M Tris-Cl (pH 
8.0)], and 3 column-volumes of buffer C [buffer B (pH 
6.8)]. Purified proteins were eluted with buffer D [buffer B 
(pH 4.5), supplemented with 200 mM EDTA], dialyzed 
against phosphate buffered saline (PBS), and then re-dis-
solved in 0.2 M sodium bicarbonate buffer containing 
0.02% SDS (pH 7.4) overnight. Small amounts of the elut-
ed samples were tested for purity on 12% SDS-PAGE. Ten 
6-week-old female BALB/c mice were used to raise antise-
rum. Recombinant mV3 protein was mixed with the same 
volume of Freund  complete adjuvant by sonication. A pro-
tein-adjuvant emulsion containing 25 µg of immunogen 
was injected subcutaneously into each mouse. The first im-
munization was followed by two booster injections every 2 
weeks with 20 µg of the protein mixed with incomplete ad-
juvant. The final immunization was given 2 weeks after the 
second booster by injecting 10 µg of recombinant protein 
via the tail vein. Blood was collected from the ophthalmic 
vein of immunized mice, from which antiserum was pre-
pared and used for Western blot analysis.
Analysis of mV3 expression in rBCG 
As described previously,17 recombinant BCG-mV3 trans-
formants were cultured in Middliebrook 7H9 broth media 
containing 25 µg/mL of kanamycin. When the cells were 
grown to 1×106 cells/mL, the culture was heat-induced, and 
then harvested at the requested time points. The cells were 
washed in PBS plus 0.05% Tween 80 and resuspended in 
1/20-volume of radioimmunoprecipitation assay buffer. 
Culture lysates were analyzed by Western blot hybridiza-
tion with anti-mV3-antiserum prepared from the previous 
step and goat-antimouse IgG (Sigma Chemical Co., St. 
Louis, MO, USA).
Immunization of BALB/c mice with rBCG-mV3 
BALB/c female mice, 5-6 weeks old, were inoculated intra-
peritoneally with heat-induced rBCG-mV3 and control 
BCG at a concentration of 1×107 cells/mouse. 
Genetic stability of the rBCG-mV3 in vivo
Immunized BALB/c mice were killed 4, 8, and 16 weeks 
after inoculation. Spleens were homogenized in PBS with 
0.05% Tween 80 (pH 7.5) and were then cultured on the 
Middlebrook 7H11 agar plate supplemented with oleic 
TTC ATT AAT TGT ACA AGA CC-3’  (EcoRI), antisense 5’ 
CAA GT CTG CAG AAT GTT ACA ATG TGC TT-3’ 
(PstI), sense 5’ CAA GT CTGCAG ATT AAT TGT ACA 
AGA CC-3’ (PstI) and antisense 5’ GCA TTA AGC TTA 
AAT GTT ACA ATG TGC TTG TC-3’ (HindIII) primers 
were designed from the sequence of HXB2, as reported pre-
viously.22 PCR-amplified cDNA were eluted from agarose 
gel and digested with BamHI, EcoRI, PstI, and HindIII. The 
PCR fragments of the 135bp of V3 DNA was ligated, and re-
amplified with the BamHI sense & HindIII antisense primer 
set. The 405bp of V3 trimer (mV3) fragments were ligated 
into pRSET B (Invitrogen, Carlsbad, CA, USA) and 
pMV261, and henceforth referred to as pRSET-mV3 and 
pMV-mV3, respectively. Recombinant pRSET-mV3 plasmid 
was introduced into an E. coli strain containing an episome 
of T7 RNA polymerase, BL21 (DE3). The pRSET-mV3/
BL21 (DE3) clone was cultured in modified M9 broth (1% 
Bacto-tryptone, 0.4% glucose, 0.5% NaCl, 1 mM MgSO4, 
0.3% KH2PO4, 0.6% NaH2PO4, and 0.1 mM NH4Cl). Re-
combinant mV3 synthesis was induced by isopropyl-beta-D-
thiogalactopyranoside (IPTG) at a final concentration of 1 
mM. pMV-mV3 recombinant plasmid was transformed into 
the Mycobacterium bovis BCG 1173-P2 Pasteur strain, as 
described previously.17 Cells were plated on Middlebrook 
7H10 agar (Difco Laboratory, Detroit, MI, USA) containing 
albumin, dextrose, catalase (ADC) enrichment, and kanamy-
cin (25 µg/mL). Kanamycin-resistant colonies were sub-cul-
tured in Middlebrook 7H10 liquid medium containing ADC 
enrichment and kanamycin for 1 week. mV3 expression was 
induced by treating the rBCG-mV3 positive clones at 45°C 
for 2 hours, as described previously.17 To extract plasmid 
DNA from the positive BCG clones, the cell pellets were re-
suspended and incubated with 400 μL of glucose-Tris-
EDTA/20 mg lysozyme at 37°C for 2-3 hours. Cells were 
disrupted by adding 300 μL of lysis buffer (2.5% SDS and 
0.3% NaOH), and 250 μL of Sol III [3M potassium acetate 
(pH 5.2)] to the reaction mixture. Supernatant was precipitat-
ed by adding the same volume of isopropanol. 
Anti-mV3 antiserum preparation 
The pRSET-mV3-transformed E. coli BL21 (DE3) culture 
was harvested, resuspended in lysis buffer [50 mM Tris-Cl 
(pH 8.0), 1 mM EDTA and 100 mM NaCl], and then lysed 
by an ultrasonic dismembrator. The lysate was dissolved in 
buffer A [6 M guanidine HCl, 0.1 M Na-phosphate and 
0.01 M Tris-Cl (pH 8.0)], centrifuged, and the supernatant 
was applied to the 50% slurry of a Ni+-NTA agarose col-Young Jae Kim 
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mV3-specific antibodies, as described previously.17 EIA 
plates were coated with 0.5 µg/mL of the purified recombi-
nant mV3 overnight. After the plates were washed 3 times 
with 0.2% Tween 20 in PBS (PBS-T) and blocked with 2% 
blotto/0.5% bovine serum albumin (BSA), 100 μL of the 
serum samples (1 μL of serum in 100 μL binding buffer) 
were added to each well and incubated at 37°C  for 1 hour. 
Plates were washed 3 times with PBS-T buffer, and incu-
bated with alkaline phosphatase-conjugated goat anti-
mouse IgG secondary antibody (Sigma Chemical Co.). P-
nitrophenyl phosphate solution was added to each well, and 
then read by an ELISA reader (Molecular Devices Inc., St. 
Louis, MO, USA) at 405 nm. Analysis of mV3-specific an-
tibodies was performed with a mouse Ig isotyping kit 
(Pharmingen, San Diego, CA, USA). 
DTH response in immunized guinea pigs  
As described previously,17 guinea pigs were administered 1 
×108 cells of live rBCG-mV3 and control BCG intraperito-
neally. Four weeks later, the mice were boosted with the 
same amount of cells via the same route. Two weeks after 
boosting, the animals were skin tested by intradermal injec-
tion of purified recombinant mV3 protein and  purified pro-
tein derivative of tuberculin (PPD). Delayed type hypersen-
sitivity (DTH) responses were evaluated by measuring 
erythema 48 hours after skin injection.  
T cell proliferation assay
Spleens were removed from mice 10 weeks and 5 months af-
ter the primary injection. The splenocytes of each immuniza-
tion group (n = 4) were pooled, and 2×105 cells/well in 
RPMI-1640 containing 2% mouse serum were cultured in 96-
well plates in the presence or absence of antigen for 120 
hours, labeled with [3H]-thymidine (1 mCi/well) for 8 hours 
prior to harvesting, and then counted on a scintillation counter.
RESULTS
Recombinant mV3 protein and polyclonal anti-mV3 
antibody 
Recombinant mV3 proteins were purified from pRSET 
B-mV3/E. coli BL21 (DE3) using a Ni+-NTA resin column 
(Fig. 2A). Polyclonal antibody specific to mV3 protein was 
obtained from BALB/c mice immunized with the recombi-
nant protein (Fig. 2B). In order to determine whether or not 
the mV3 protein shared similar properties with the other V3 
acid, albumin, dextrose, catalase (OADC) enrichment (Dif-
co Laboratory), and 25 μg/mL of kanamycin. Kanamycin-
resistant colonies were subcultured in Middlebrook 7H9 
liquid medium containing ADC enrichment and kanamy-
cin. Lysates from these cultures were tested for mV3 ex-
pression by Western blot, and plasmid DNA extracted from 
the recovered BCG clone was tested for its integrity by 
PCR with mV3-covering PCR primer set.
Antibody titration and IgG isotyping
Blood was obtained from the ophthalmic vein from BALB/
c mice every other week beginning 5-6 weeks after immu-
nization, and antiserum was assessed by ELISA to measure 
Fig. 2. (A) V3-trimer was cloned into pRSET-B vector, and expressed in E. 
coli BL21 (DE3). Whole cell lysates or purified protein was separated on a 
SDA-PAGE. Lane 1, pRSET/B control vector-transformed cell lysate; lane 2, 
pRSET-mV3-transformed cell lysate; lane 3, Ni
+-NTA resin-purified recom-
binant mV3 protein. (B) Western blot analysis of V3-concatamer (three V3) 
expressed in bacteria with 2 different antisera. pRSET/B control vector-
transformed cell lysate (1) and pRSET-mV3-transformed cell lysate (2) were 
separated on a SDS-PAGE, and then assessed by Western blot analysis 
with mouse anti-3V3-antibody (a) and rabbit anti-gp120 antibody (b). SDA-
PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; V3, third 
variable.
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Fig. 3. (A) Western blot analysis of rBCG-mV3 lysates with anti-V3 antise-
rum. Cultures of rBCG-mV3 were heat-induced at 45  for 2 hours in the log 
phase, and the same amounts of cells were harvested from the culture in 2 
week intervals. M, marker; lane 1, BCG-pMV control; lane 2, BCG-mV3 (2 
weeks); lane 3, BCG-mV3 (4 weeks);  lane 4, BCG-mV3 (6 week) after a sin-
gle heat-shock; lane 5, mV3-expressing E. coli lysate as a positive control.   
(B) PCR amplification of the plasmid extracted from the kanamycin-resis-
tant rBCG that was isolated from the spleen of immunized mice was per-
formed with V3-specific primer set. Each lane shows a pMV-mV3 positive 
control (1), pMV261 negative control (2), and plasmid recovered from the 
rBCG-mV3-immunized mice 4 weeks (3) and 8 weeks after immunization 
(4). (C) Western blot analysis of rBCG-mV3 recovered from immunized mice 
with anti-mV3 sera. Each lane shows BCG-pMV (1), rBCG-mV3 (2), and pR-
SET-mV3 / E. coli BL21 (DE3) lysate (3). BCG, Bacille Calmette-Guérin; PCR, 
polymerase chain reaction.
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BALB/c mice. Six weeks later, V3-specific antibody was as-
sessed in the antiserum collected from the immunized mice 
every 2 weeks. As shown in Fig. 4A, mV3-specific poly-
clonal antibodies were induced and maintained for at least 14 
weeks. The amount of V3-specific polyclonal antibodies rap-
idly increased in the immunized mice, reached a maximum 
at week 10, and then lasted for over 4 weeks (Fig. 4A). The 
specific antibodies completely disappeared when examined 
10 months after primary inoculation (data not shown). The 
specificity of polyclonal antibodies to mV3 was further evi-
denced by Western blot analysis with purified mV3 and con-
trol BCG lysates (Fig. 4B). However, HIV-1 replication was 
not efficiently blocked by the antiserum (Fig. 4C). 
Recombinant BCG-mV3 elicited mV3-specific DTH 
responses in guinea pigs
In general, recombinant BCG is well-known to induce strong 
DTH responses against BCG and introduced foreign anti-
gens in immunized animals.23,24 The mV3-specific DTH was 
assessed in the guinea pigs immunized with rBCG-mV3. 
Two weeks after the second inoculation, animals were tested 
for the reciprocal DTH response to mV3 protein and PPD. 
proteins, recombinant protein was assessed by Western blot 
analysis with anti-gp120 polyclonal antibodies. The mV3 
protein was detected by mouse anti-V3 and rabbit anti-
gp120 polyclonal antibodies (Fig. 2B). These results sug-
gest that V3-specific antibodies induced by mV3-immuni-
zation are likely to interact with wild type V3 motif.
Genetic stability of rBCG-mV3 in vitro and in vivo
pMV-mV3 recombinant plasmid was transformed into 
BCG by electroporation, as described in the Materials and 
Methods. The rBCG-mV3 stably expressed mV3 over 6 
weeks when examined every 2 weeks (Fig. 3A). BALB/c 
mice were immunized with rBCG-mV3. The rBCG-mV3 
isolated from the mice 8 weeks after immunization still har-
bored the inserted mV3 (Fig. 3B) and expressed mV3 pro-
tein (Fig. 3C). These data indicate that the rBCG-mV3 is 
genetically stable, not only in vitro, but also in vivo.
Recombinant BCG-mV3 was efficient in inducing V3-
specific humoral immunity which persisted for at least 
14 weeks
After a single heat shock, the rBCG-mV3 was injected into 
Table 1. DTH Response Against Recombinant mV3 in Guinea Pigs
Skin reaction (diameter; mm)
Immunization Purified mV3 protein PPD
5 μg / 0.1 mL 10 μg / 0.1 mL 5 TU / 0.1 mL
None 0 0 0
BCG-pMV 0 0 12.5 ± 0.82
BCG-mV3 3.5 ± 0.41 4.0 ± 0.71 14.5 ± 0.95 
DTH, delayed type hypersensitivity; PPD, purified protein derivatives; TU, tuberculin unit. 
Fig. 4. rBCG-mV3 induces V3-specific antibody in BALB/c mice. (A) Six-week old BALB/c mice were inoculated with control (transformed with pMV261 emp-
ty vector) and recombinant BCG (rBCG-mV3) at a concentration of 1 × 10
7 cells/mouse intraperitoneally. The titer of anti-V3 antibody in the serum obtained 
from the immunized mice every 2 weeks were assessed by ELISA as described in the Materials and Methods. Anti-serum was collected from the rBCG-
mV3-immunized mice 6 weeks after primary inoculation. (B) Cell lysates or purified mV3 were examined by Western blot analysis with the antiserum ob-
tained from the mice immunized with rBCG-mV3. The arrow indicates the band of purified mV3 protein. (C) C8166 human T cell line was infected with 1 MOI 
of HIV-1 (HXB2), which was pre-incubated with mouse anti-rBCG-mV3 sera or control anti-BCG sera at 37  for 1 hr. Cells were harvested and lyzed at the in-
dicated time point and then p24 antigen was assessed by Western blot analysis with anti-p24 monoclonal antibody. OD, optical density; PI, postinoculation; 
MOI, multiplicities of infection; BCG, Bacille Calmette-Guérin.
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response,25,26 and IgG2a results from the Th1 response.26 
Based on IgG isotyping analysis, V3-specific IgG2a was 
prevalent in the sera of mice immunized with recombinant 
BCG-mV3, whereas IgG1 and IgG3 isotypes were relative-
ly lower (Fig. 5B). This means that rBCG-mV3 was very 
effective in inducing Th1-oriented cell-mediated immunity 
in immunized mice. 
DISCUSSION
A rBCG-mV3, expressing the trimer of HIV-1 V3, was 
constructed by introducing pMV-mV3 plasmid into BCG 
as a vaccine vector. Based on the information that Gly-Pro-
Gly-Arg-Ala-Phe residues (GxGRxF) are highly conserved 
in HIV-1 variants27,28  and play a crucial role in the interac-
tion with chemokine receptor,29 these sequences have been 
included into the V3-trimer. 
Not only humoral immunity but also Th1-oriented cellular 
immunity are essential for protection against HIV-1 infec-
tion.30 BCG is well-known for its safety and efficacy in the 
induction of strong cell-mediated immunity.31 However, even 
a BCG as a live attenuated vaccine caused tuberculosis-like 
disease in simian immunodeficiency virus (SIV)-infected 
monkeys is probably due to a loss of T-cell immunity.32 
Therefore, it is advisable to develop a recombinant BCG as a 
preventative vaccine rather than therapeutic vaccine against 
HIV-1.33 
The DTH responses to mV3 in the immunized animals 
were positive 6 weeks after primary inoculation (Table 1). 
Recombinant BCG-mV3 induced relatively weak DTH re-
sponse against mV3 protein compared with that against 
PPD in immunized guinea pigs, which was attributable to 
the amount of mV3 weakly expressed in rBCG-mV3. 
Cellular immune responses in mice immunized with 
rBCG-mV3
Sometimes there is a discrepancy between the DTH re-
sponse and T cell proliferation. The T cell responses in im-
munized mice were examined. The splenocytes of mice im-
munized with rBCG-mV3 or control BCG were isolated 10 
weeks and 5 months after immunization, and subjected to a 
T cell proliferation assay. The stimulation index (SI) was 
determined, as described in the Materials and Methods. The 
SI in response to mV3 in mice immunized with rBCG-
mV3 was about three times as strong as that in mice immu-
nized with control BCG (BCG-PMV), and the SI to mV3 
assessed 5 months after immunization was markedly en-
hanced compared with that assessed 10 weeks after immu-
nization (Fig. 5A). These results imply that rBCG-mV3 is 
able to produce and maintain the memory T cells against 
mV3 in immunized animals during induction of cellular 
immunity against BCG. 
mV3-specific IgG2a was prevalent in anti-sera
It is well established that IgG1 and IgG3 represent the Th2 
Fig. 5. (A) Lymphocyte proliferation assay in response to recombinant-mV3 antigen stimulation in T cell-enriched splenocytes of immu-
nized mice. Spleens were removed from 3 mice per group 10 weeks and 5 months after immunization with rBCG-mV3 and control BCG 
(BCG-PMV), respectively. Lymphocyte proliferation assay was performed by measuring the [
3H]-thymidine incorporation, and is ex-
pressed as the mean  SD stimulation indices in triplicate and three independent experiments. (B) Anti-mV3 antibody isotyping was per-
formed using a monoclonal antibody-based mouse Ig isotyping kit and expressed by percentage for each isotype and subclass. Anti-
serum was obtained from mice 10 weeks after immunization with rBCG-mV3. Anti-serum was pre-cleared with BCG lysates and then 
used for ELISA. PI, postinoculation; BCG, Bacille Calmette-Guérin.
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munity, recombinant BCG is such a good Th1 immune stim-
ulator that it pushes for Th1 development even in BALB/c 
mice, as shown previously in IL-12-mediated Th1 develop-
ment in BALB/c mice.36 However, to make it clearer, DTH 
response in immunized BALB/c mice remains to be traced 
by measuring footpad swelling, as reported previously.37
In summary, recombinant BCG expressing mV3 effi-
ciently induced humoral and cellular immunities against the 
V3 domain. Particularly noteworthy is that rBCG-mV3 in-
duced long-lasting mV3-specific cellular immunity in im-
munized animals.  
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